National Cancer Institute to Grant Exclusive Patent License to Connectyx for Glioblastoma Treatment

Summary

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Connectyx Technologies Holdings Group to develop an antibody-drug conjugate targeting glioblastoma, either alone or in combination with other immunotherapy drugs.